Tenaya Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TNYA Nasdaq 2836 www.tenayatherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tenaya Therapeutics, Inc.

Morgan Stanley Reduces PT on Tenaya Therapeutics (TNYA), Keeps Constructive Stance on U.S. Small- to Mid-Cap Biotech - Jan 12th, 2026 2:23 am
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones - Jan 9th, 2026 6:30 am
Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed - Dec 14th, 2025 11:10 am
BC-Most Active Stocks - Dec 12th, 2025 8:30 am
Tenaya Therapeutics Announces Pricing of Public Offering - Dec 11th, 2025 10:16 pm
Tenaya Therapeutics Says FDA Hold Removed on TN-201, Posts Positive TN-401 Interim Data, Plans Stock, Warrant Offering - Dec 11th, 2025 3:44 pm
Tenaya Therapeutics Announces Proposed Public Offering - Dec 11th, 2025 2:02 pm
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC - Dec 11th, 2025 2:01 pm
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy - Dec 11th, 2025 2:01 pm
Will Tenaya Therapeutics (NASDAQ:TNYA) Spend Its Cash Wisely? - Nov 20th, 2025 3:45 am
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 10th, 2025 5:00 am
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy - Nov 8th, 2025 9:25 am
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025 - Nov 4th, 2025 3:30 pm
Tenaya Therapeutics (TNYA): Evaluating Valuation After Investor Buzz on MyPEAK-1 and RIDGE-1 Clinical Updates - Oct 10th, 2025 9:10 am
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference - Oct 9th, 2025 2:05 pm
Can Tenaya Therapeutics’ Leadership Messaging Shape Long-Term Perceptions and Value Creation for TNYA? - Oct 9th, 2025 4:11 am
Tenaya Therapeutics to Participate in Upcoming October Investor Conferences - Oct 2nd, 2025 2:05 pm
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Sep 18th, 2025 2:05 pm
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - Sep 2nd, 2025 2:05 pm
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025 - Aug 31st, 2025 8:15 am